Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m

Insiders who bought Prelude Therapeutics Incorporated (NASDAQ:PRLD) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$62m as a result of the stock's 34% gain over the same period. Put another way, the original US$656.7k acquisition is now worth US$2.75m. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. The Last 12 Months Of Insider Transactions At Prelude Therapeutics In the last twelve months, the biggest single purchase by an insider was when Founder Krishna Vaddi bought US$467k worth of shares at a price of US$0.69 per share. Even though the purchase was made at a significantly lower price than the recent price (US$2.94), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive. Prelude Therapeutics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! See our latest analysis for Prelude Therapeutics NasdaqGS:PRLD Insider Trading Volume December 30th 2025 Prelude Therapeutics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. Does Prelude Therapeutics Boast High Insider Ownership? Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 5.4% of Prelude Therapeutics shares, worth about US$13m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. So What Do The Prelude Therapeutics Insider Transactions Indicate? There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in Prelude Therapeutics and their transactions don't cause us concern. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. You'd be interested to know, that we found 1 warning sign for Prelude Therapeutics and we suggest you have a look. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTech